What to watch for as Novartis heads to the FDA with a novel cancer therapy – STAT
STAT |
What to watch for as Novartis heads to the FDA with a novel cancer therapy
STAT Novartis' therapy, called CTL019, is a customized treatment made by harvesting patients' white blood cells and rewiring them to home in on tumors. It's the first so-called CAR–T therapy to come before the FDA, leading a pack of novel treatments that … Before Key Meeting, FDA Stresses Risks of Novartis CAR–T Cancer Therapy Safety issues for Novartis CAR–T therapy main focus of FDA FDA panel to focus on safety of Novartis gene therapy drug |
